Description: Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
Home Page: www.nanobiotix.com
60 rue de Wattignies
Paris,
75012
France
Phone:
33 1 40 26 04 70
Officers
| Name | Title |
|---|---|
| Mr. Laurent Levy Ph.D. | Co-Founder, President of the Executive Board & CEO |
| Mr. Bart Van Rhijn | Chief Financial & Business Officer and Member of Executive Board |
| Ms. Anne-Juliette Hermant M.A. | Chief People Officer & Member of Executive Board |
| Dr. Louis Kayitalire M.D. | Chief Medical Officer |
| Mr. Earl J. Bergey Ph.d. | Co-Founder |
| Mr. Craig West CFA | Senior Vice President of Investor Relations |
| Mr. Brandon Owens | VP of Strategic Marketing & Corporate Communication |
| Ms. Margaret Galluzzi | VP & Global Head of Clinical Operations |
| Dr. Leonard A. Farber M.D. | Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 46.2963 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 59.1644 |
| Price-to-Sales TTM: | 3.2574 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 110 |